GleamWall
中文EN

ACTU ACTUATE THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1652935 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY23.4%
TTM EPS YoY-323.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-364.7%
ROA-176.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets125.1%
Debt / equity—
Current ratio0.73x
Interest coverage-925.44x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-22.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.81M$2.07M$2.57M$2.13M$2.18M$2.76M$3.22M$3.69M
SG&A expense$1.63M$2.84M$3.14M$2.56M$3.29M$3.20M$3.15M$2.87M
Operating income-$3.44M-$4.91M-$5.71M-$4.69M-$5.47M-$5.97M-$6.37M-$6.56M
Interest expense$5,063$5,063$5,062$5,062$5,063$5,062$5,063$5,076
Net income-$3.42M-$4.87M-$5.63M-$4.55M-$5.41M-$5.95M-$6.32M-$6.45M
EPS (basic)-0.14-0.20-0.24—-0.25-0.30-0.32—
EPS (diluted)-0.14-0.20-0.24—-0.25-0.30-0.32—
Weighted avg. shares (diluted)24.22M23.87M23.54M—21.39M19.65M19.50M—
Balance sheet
Cash & equivalents$2.10M$4.43M$8.13M$13.16M$16.92M$6.49M$3.89M$8.64M
Current assets$2.65M$4.75M$8.52M$13.64M$17.44M$6.69M$4.25M$9.21M
Total assets$3.22M$5.20M$8.91M$14.04M$17.71M$6.97M$4.48M$9.32M
Current liabilities$3.62M$3.81M$4.72M$5.71M$6.37M$9.20M$9.15M$8.80M
Total liabilities$4.03M$4.21M$5.13M$6.11M$6.78M$9.62M$9.57M$9.21M
Shareholders' equity-$808,966$989,152$3.78M$7.92M$10.94M-$2.65M-$5.09M$104,186
Shares outstanding24.75M24.01M23.71M23.25M23.24M20.47M19.53M19.53M
Cash flow statement
Operating cash flow-$2.95M-$4.41M-$5.02M-$3.74M-$6.68M-$4.17M-$4.62M-$4.77M
Financing cash flow$626,781$696,960-$8,092-$29,297$17.11M$6.78M-$133,477-$109,412
Stock-based compensation$970,824$1.34M$1.36M$1.54M$1.80M$1.58M$1.13M$1.19M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.